EXEL - Exelixis Inc Stock Price, Fair Value and News

21.27USD-0.10 (-0.47%)Market Closed

Market Summary

USD21.27-0.10

Market Closed

-0.47%

EXEL Stock Price

View Fullscreen

EXEL RSI Chart

EXEL Valuation

Market Cap

6.2B

Price/Earnings (Trailing)

30.22

Price/Sales (Trailing)

3.36

EV/EBITDA

47.56

Price/Free Cashflow

22.16

EXEL Price/Sales (Trailing)

EXEL Profitability

EBT Margin

6.12%

Return on Equity

9.64%

Return on Assets

7.31%

Free Cashflow Yield

4.51%

EXEL Fundamentals

EXEL Revenue

Revenue (TTM)

1.8B

Rev. Growth (Yr)

4.02%

Rev. Growth (Qtr)

-11.35%

EXEL Earnings

Earnings (TTM)

205.1M

Earnings Growth (Yr)

-6.77%

Earnings Growth (Qtr)

-56.36%

Breaking Down EXEL Revenue

Last 7 days

-2.9%

Last 30 days

-6.7%

Last 90 days

5.1%

Trailing 12 Months

10.9%

How does EXEL drawdown profile look like?

EXEL Financial Health

Current Ratio

3.46

EXEL Investor Care

Buy Backs (1Y)

10.55%

Diluted EPS (TTM)

0.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.8B	0	0	0
2023	1.7B	1.7B	1.8B	1.8B
2022	1.5B	1.6B	1.6B	1.6B
2021	1.0B	1.2B	1.3B	1.4B
2020	979.2M	998.4M	957.8M	987.5M
2019	855.6M	909.8M	956.1M	967.8M
2018	585.3M	672.4M	745.3M	853.8M
2017	256.9M	319.7M	410.0M	452.5M
2016	43.2M	71.5M	123.8M	191.5M
2015	29.6M	31.0M	34.6M	37.2M
2014	26.6M	21.3M	22.1M	25.1M
2013	38.6M	42.7M	34.8M	31.3M
2012	272.3M	247.9M	132.9M	47.5M
2011	178.7M	163.3M	237.1M	289.6M
2010	0	162.9M	173.9M	185.0M
2009	0	0	0	151.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Exelixis Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	garber alan m	sold	-461,112	24.01	-19,205	-
Mar 21, 2024	garber alan m	acquired	459,719	19.57	23,491	-
Feb 23, 2024	senner christopher j.	acquired	-	-	82,121	evp and cfo
Feb 23, 2024	haley patrick j.	acquired	-	-	63,350	evp, commercial
Feb 23, 2024	aftab dana	acquired	-	-	63,350	cso/evp disc & trans research
Feb 23, 2024	peterson amy c.	acquired	-	-	82,121	evp prod dev & med aff & cmo
Feb 23, 2024	hessekiel jeffrey	acquired	-	-	63,350	evp, general counsel & sec
Feb 23, 2024	morrissey michael	acquired	-	-	241,670	president and ceo
Feb 23, 2024	haley patrick j.	sold	-1,008,580	21.45	-47,020	evp, commercial
Feb 21, 2024	johnson david edward	bought	3,932,730	20.6986	190,000	-

Which funds bought or sold EXEL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	WELLS FARGO & COMPANY/MN	added	68.14	893,285	2,240,350	-%
May 10, 2024	Covestor Ltd	added	39.4	47,000	171,000	0.11%
May 10, 2024	CORNERCAP INVESTMENT COUNSEL INC	new	-	1,185,500	1,185,500	0.18%
May 10, 2024	CREDIT SUISSE AG/	added	2.08	81,107	8,370,900	0.01%
May 10, 2024	PRINCIPAL SECURITIES, INC.	added	291	16,052	21,642	-%
May 10, 2024	Kepos Capital LP	new	-	1,551,000	1,551,000	0.40%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	reduced	-31.24	-13,583,000	28,899,000	0.10%
May 10, 2024	O'Neil Global Advisors, Inc.	sold off	-100	-233,000	-	-%
May 10, 2024	OAK ASSOCIATES LTD /OH/	unchanged	-	-31,595	2,883,600	0.20%
May 10, 2024	Sargent Investment Group, LLC	reduced	-6.03	-501,344	6,608,090	1.45%

Are Funds Buying or Selling EXEL?

Are funds buying EXEL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EXEL

No. of Funds

Unveiling Exelixis Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	renaissance technologies llc	5.16%	15,615,716	SC 13G
Feb 13, 2024	vanguard group inc	10.18%	31,671,090	SC 13G/A
Jan 24, 2024	blackrock inc.	11.6%	36,013,885	SC 13G/A
Jun 02, 2023	caligan partners lp	0.28%	910,730	SC 13D/A
Jun 02, 2023	farallon capital partners, l.p.	0.7%	2,252,820	SC 13D/A
Apr 07, 2023	farallon capital partners, l.p.	0.6%	1,959,620	SC 13D/A
Mar 27, 2023	caligan partners lp	0.26%	850,000	SC 13D/A
Mar 27, 2023	farallon capital partners, l.p.	0.6%	1,959,620	SC 13D/A
Mar 20, 2023	caligan partners lp	0.26%	850,000	SC 13D
Mar 20, 2023	farallon capital partners, l.p.	0.6%	1,959,620	SC 13D

Recent SEC filings of Exelixis Inc

View All Filings

Date Filed	Form Type	Document
May 13, 2024	144	Notice of Insider Sale Intent
May 10, 2024	8-K	Current Report
May 08, 2024	SC 13D/A	13D - Major Acquisition
May 07, 2024	144	Notice of Insider Sale Intent
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Mar 29, 2024	8-K	Current Report

Peers (Alternatives to Exelixis Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Exelixis Inc News

Latest updates

Exelixis Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-11.3%	425	480	472	470	409	424	412	419	356	451	328	385	270	270	231	259	227	240	272	240	215
Costs and Expenses	-0.5%	396	398	490	392	380	472	329	336	273	334	277	262	275	246	274	184	174	163	156	148	131
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	163	156	148	131
S&GA Expenses	-13.3%	114	131	138	142	131	119	115	123	103	99.00	102	98.00	102	82.00	88.00	60.00	63.00	58.00	51.00	59.00	60.00
R&D Expenses	-6.9%	228	245	333	233	234	337	199	199	157	222	163	149	159	154	177	115	102	94.00	97.00	82.00	63.00
EBITDA Margin	-1.2%	0.07*	0.08*	0.08*	0.08*	0.08*	0.08*	0.08*	0.08*	0.08*	0.09*	0.10*	0.11*	-	-	-	-	-	-	-	-	-
Income Taxes	-31.8%	12.00	18.00	5.00	19.00	8.00	-1.25	19.00	18.00	17.00	23.00	15.00	29.00	-3.62	-0.26	-5.98	14.00	11.00	16.00	25.00	21.00	15.00
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	125	-2.01	28.00	-38.02	81.00	60.00	85.00	123	100	91.00
EBT Margin	-0.9%	0.06*	0.06*	0.06*	0.07*	0.07*	0.07*	0.07*	0.07*	0.07*	0.08*	0.09*	0.10*	-	-	-	-	-	-	-	-	-
Net Income	-56.4%	37.00	86.00	1.00	81.00	40.00	-30.17	73.00	71.00	69.00	95.00	38.00	96.00	2.00	28.00	-32.04	67.00	49.00	69.00	97.00	79.00	76.00
Net Income Margin	-2.2%	0.11*	0.11*	0.05*	0.10*	0.09*	0.11*	0.19*	0.18*	0.20*	0.16*	0.13*	0.08*	-	-	-	-	-	-	-	-	-
Free Cashflow	2406.2%	59.00	-2.56	108	115	72.00	64.00	105	24.00	142	90.00	69.00	161	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-4.7%	2,804	2,942	2,977	3,142	3,143	3,071	2,961	2,881	2,654	2,616	2,448	2,367	2,191	2,137	2,111	2,047	1,956	1,886	1,785	1,643	1,542
Current Assets	-1.9%	1,292	1,318	1,443	1,591	1,638	1,619	1,842	1,852	1,843	1,835	1,662	1,593	1,434	1,445	1,408	1,395	1,137	1,011	972	957	946
Cash Equivalents	-1.3%	260	263	397	464	542	503	677	638	737	664	598	539	420	321	336	529	359	268	243	371	375
Inventory	21.8%	21.00	17.00	25.00	29.00	30.00	33.00	27.00	33.00	28.00	27.00	28.00	25.00	25.00	21.00	19.00	17.00	15.00	13.00	13.00	12.00	10.00
Net PPE	-1.2%	127	129	121	115	116	111	108	109	106	104	100	95.00	78.00	67.00	56.00	52.00	48.00	49.00	49.00	51.00	51.00
Goodwill	0%	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00	64.00
Liabilities	-0.4%	676	678	629	615	588	583	470	490	360	406	335	324	279	258	259	213	208	200	181	154	157
Current Liabilities	-5.4%	373	394	377	340	328	324	302	305	289	338	270	255	213	205	201	143	140	143	141	111	125
Shareholder's Equity	-6.0%	2,128	2,264	2,348	2,528	2,555	2,488	2,491	2,391	2,294	2,211	2,112	2,043	1,911	1,879	1,852	1,833	1,748	1,686	1,604	1,489	1,385
Retained Earnings	-49.4%	-258	-173	-126	11.00	6.00	-34.22	-4.05	-77.26	-147	-216	-311	-349	-445	-447	-475	-443	-510	-559	-628	-725	-804
Additional Paid-In Capital	-2.0%	2,392	2,441	2,487	2,531	2,558	2,537	2,513	2,477	2,448	2,428	2,422	2,391	2,354	2,322	2,321	2,269	2,258	2,242	2,229	2,212	2,189
Shares Outstanding	-2.6%	295	303	311	320	324	324	321	320	320	315	315	314	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	4,700	-	-	-	6,831	-	-	-	5,680	-	-	-	6,400	-	-	-	5,731	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	551.0%	69.00	11.00	117	121	84.00	74.00	110	31.00	148	96.00	83.00	182	40.00	33.00	18.00	102	56.00	158	76.00	132	162
Share Based Compensation	-21.4%	19.00	24.00	40.00	25.00	17.00	26.00	37.00	25.00	20.00	23.00	34.00	28.00	35.00	19.00	56.00	16.00	14.00	16.00	13.00	15.00	13.00
Cashflow From Investing	81.1%	112	62.00	35.00	-73.78	-49.59	-245	-68.95	-135	-74.54	-13.05	-21.24	-70.84	62.00	-29.51	-207	73.00	33.00	-130	-206	-142	-107
Cashflow From Financing	10.7%	-184	-206	-219	-124	5.00	-2.00	-2.04	4.00	0.00	-17.99	-2.88	9.00	-2.65	-18.69	-3.43	-5.15	2.00	-3.00	3.00	7.00	5.00
Buy Backs	-10.0%	185	206	220	128	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EXEL Income Statement

2024-03-29

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 29, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 425,226	$ 408,788
Operating expenses:
Cost of goods sold	21,256	14,315
Research and development	227,689	234,246
Selling, general and administrative	113,984	131,397
Restructuring	32,835	0
Total operating expenses	395,764	379,958
Income from operations	29,462	28,830
Interest income	19,894	19,502
Other expense, net	(89)	(54)
Income before income taxes	49,267	48,278
Provision for income taxes	11,950	8,250
Net income	$ 37,317	$ 40,028
Net income per share:
Basic (in dollars per share)	$ 0.12	$ 0.12
Diluted (in dollars per share)	$ 0.12	$ 0.12
Weighted-average common shares outstanding:
Basic (in shares)	300,757	324,420
Diluted (in shares)	305,530	326,279
Net product revenues
Revenues:
Total revenues	$ 378,523	$ 363,400
License revenues
Revenues:
Total revenues	44,676	38,292
Collaboration services revenues
Revenues:
Total revenues	$ 2,027	$ 7,096

EXEL Balance Sheet

2024-03-29

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 29, 2024	Dec. 29, 2023
Current assets:
Cash and cash equivalents	$ 259,561	$ 262,994
Short-term investments	703,695	732,308
Trade receivables, net	240,577	237,407
Inventory	21,106	17,323
Prepaid expenses and other current assets	67,490	67,926
Total current assets	1,292,429	1,317,958
Long-term investments	629,561	728,717
Property and equipment, net	127,222	128,731
Deferred tax assets, net	361,578	361,145
Goodwill	63,684	63,684
Right-of-use assets and other	329,278	342,122
Total assets	2,803,752	2,942,357
Current liabilities:
Accounts payable	26,069	33,768
Accrued compensation and benefits	72,958	93,325
Accrued clinical trial liabilities	59,337	71,615
Rebates and fees due to customers	75,651	59,619
Accrued collaboration liabilities	34,704	27,533
Other current liabilities	104,291	108,417
Total current liabilities	373,010	394,277
Long-term portion of operating lease liabilities	201,466	189,944
Other long-term liabilities	101,268	94,224
Total liabilities	675,744	678,445
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued	0	0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 295,032 and 302,793 at March 31, 2024, and December 31, 2023, respectively	295	303
Additional paid-in capital	2,391,865	2,440,710
Accumulated other comprehensive loss	(5,204)	(3,750)
Accumulated deficit	(258,948)	(173,351)
Total stockholders’ equity	2,128,008	2,263,912
Total liabilities and stockholders' equity	$ 2,803,752	$ 2,942,357

About Exelixis Inc

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

CEO	Dr. Michael M. Morrissey Ph.D.
WEBSITE	exelixis.com
INDUSTRY	Biotechnology
EMPLOYEES	1223

Exelixis Inc Frequently Asked Questions

What is the ticker symbol for Exelixis Inc? What does EXEL stand for in stocks?

EXEL is the stock ticker symbol of Exelixis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exelixis Inc (EXEL)?

As of Mon May 13 2024, market cap of Exelixis Inc is 6.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXEL stock?

You can check EXEL's fair value in chart for subscribers.

What is the fair value of EXEL stock?

You can check EXEL's fair value in chart for subscribers. The fair value of Exelixis Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exelixis Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EXEL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exelixis Inc a good stock to buy?

The fair value guage provides a quick view whether EXEL is over valued or under valued. Whether Exelixis Inc is cheap or expensive depends on the assumptions which impact Exelixis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXEL.

What is Exelixis Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, EXEL's PE ratio (Price to Earnings) is 30.22 and Price to Sales (PS) ratio is 3.36. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXEL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exelixis Inc's stock?

In the past 10 years, Exelixis Inc has provided 0.204 (multiply by 100 for percentage) rate of return.